Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

Hiroaki Seino, Yukiko Onishi, Yusuke Naito, Mitsuhisa Komatsu, Hiroaki Seino, Yukiko Onishi, Yusuke Naito, Mitsuhisa Komatsu

Abstract

Background: The GetGoal-L-Asia and -S trials were multi-center trials conducted in 4 and 16 countries, respectively including Japan that evaluated the efficacy and safety of lixisenatide add-on treatment vs. placebo among patients with type 2 diabetes. The aims of this study were to determine the efficacy and safety of lixisenatide add-on treatment among Japanese patient groups.

Methods: All Japanese intent-to-treat patients with baseline and endpoint HbA1c measurements were included in the meta-analyses. Subgroup analyses were carried out for patients with low (<8 %) and high (≥8 %) baseline HbA1c levels, low (<25 kg/m(2)) and high (≥25 kg/m(2)) baseline body mass index (BMI), short (<10 years) and long (≥10 years) durations of diabetes, and for those <65 and ≥65 years of age.

Results: The overall study population of Japanese type 2 diabetes patients included 143 patients (mean age: 59.0 years; 35 % female) treated with lixisenatide and 136 patients treated with placebo (mean age: 57.8 years; 32 % female). Among the subgroups, lixisenatide treatment vs. placebo was associated with greater change in HbA1c (Low HbA1c -0.80 %, p < 0.0001; High HbA1c -1.19 %, p < 0.0001; low BMI -0.88 %, p < 0.0001; high BMI -1.28 %, p < 0.0001; short diabetes duration -1.28 %, p < 0.0001; long diabetes duration -0.93 %, p < 0.0001; <65 years: -1.00 %, p < 0.0001; ≥65 years -1.24 %, p < 0.0001). Additionally, among the subgroups, lixisenatide treatment vs. placebo was associated with greater change in post-prandial glucose.

Conclusions: For Japanese type 2 diabetes patients lixisenatide may be an efficacious and safe add-on therapy leading to improved glycemic outcomes. GetGoal-L-Asia NCT01169779 GetGoal-S NCT00713830.

Keywords: GLP-1 receptor agonists; Lixisenatide; Type 2 diabetes.

Figures

Fig. 1
Fig. 1
Forest plot of hba1c treatment differences among Japanese type 2 diabetes patient subgroups

References

    1. Ministry of Health (1997) National diabetes survey. . Accessed 20 Mar 2015.
    1. Ministry of Health, Labour and Welfare (2012) National Health and Nutrition Survey. . Accessed 20 Mar 2015.
    1. Goto A, Goto M, Noda M, Tsugane S. Incidence of type 2 diabetes in Japan: a systematic review and meta-analysis. PLoS One. 2013;8:e74699. doi: 10.1371/journal.pone.0074699.
    1. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev. 2009;25:705–716. doi: 10.1002/dmrr.1012.
    1. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66(1 Suppl):S37–S43. doi: 10.1016/j.diabres.2003.11.024.
    1. Iwahashi H, Okauchi O, Ryo M, Noguchi M, Morita S, Kishida K, et al. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Investig. 2012;3:271–275. doi: 10.1111/j.2040-1124.2011.00180.x.
    1. Moller JB, Pedersen M, Tanaka H, Ohsugi M, Overgaard RV, Lynge J, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2014;37:796–804. doi: 10.2337/dc13-0598.
    1. WHO Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163. doi: 10.1016/S0140-6736(03)15268-3.
    1. Nisal K, Kela R, Khunti K, Davies MJ. Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Med. 2012;10:152. doi: 10.1186/1741-7015-10-152.
    1. Seino Y, Min KW, Niemoeller E, Takami A. EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes Obes Metab. 2012;14:910–917. doi: 10.1111/j.1463-1326.2012.01618.x.
    1. Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S) J Diabetes Complications. 2014;28:386–392. doi: 10.1016/j.jdiacomp.2014.01.012.
    1. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742. doi: 10.1038/nrendo.2012.140.
    1. Scheen AJ. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9:385–399. doi: 10.1586/17512433.2016.1141046.
    1. Seino Y, Ikeda Y, Niemoeller E, Watanabe D, Takagi H, Yabe D, et al. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes insufficiently controlled with basal insulin ± sulphonylurea: a subanalysis of the GetGoal-L-Asia study. Horm Metab Res. 2015;47:895–900. doi: 10.1055/s-0035-1549875.
    1. Onishi Y, Niemoeller E, Ikeda Y, Takagi H, Yabe D, Seino Y. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: subanalysis of GetGoal-S. J Diabetes Invest. 2015;6:201–209. doi: 10.1111/jdi.12275.
    1. Schmidt LJ, Habacher W, Augustin T, Krahulec E, Semlitsch T. A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:769–779. doi: 10.1111/dom.12269.
    1. Seino Y, Takami A, Boka G, Niemoeller E, Raccah D. PDY6797 investigators. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulfonylureas with/without metformin. Diabetes Obes Metab. 2014;16:739–747. doi: 10.1111/dom.12276.
    1. Wang JS, Tu ST, Lee IT, Lin SD, Lin SY, Su SL, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27:79–84. doi: 10.1002/dmrr.1149.
    1. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–B29.
    1. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl. 2002;129:5–11.
    1. Standl E, Schell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care. Diabetes Care. 2011;34(Suppl 2):S120–S127. doi: 10.2337/dc11-s206.
    1. Nakanishi S, Yoneda M, Maeda S. Impact of glucose excursion and mean glucose concentration in oral glucose-tolerance test on oxidative stress among Japanese Americans. Diabetes Metab Syndr Obes. 2013;6:427–433.
    1. Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci. 2013;14:21525–21550. doi: 10.3390/ijms141121525.
    1. Mo Y, Zhou J, Li M, Wang Y, Bao Y, Ma X, et al. Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients. Cardiovasc Diabetol. 2013;12:15. doi: 10.1186/1475-2840-12-15.
    1. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, ELIXA Investigators Lixisenatide in patients with type 2 diabetes and coronary syndrome. N Engl J Med. 2015;373:2247–2257. doi: 10.1056/NEJMoa1509225.
    1. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405.
    1. Anton SD, Karabetian C, Naugle K, Buford TW. Obesity and diabetes as accelerators of functional decline; can lifestyle interventions maintain functional status in high risk older adults? Exp Gerontol. 2013;48:888–897. doi: 10.1016/j.exger.2013.06.007.
    1. Umegaki H. Sarcopenia and diabetes: hyperglycemia is a risk factor for age-associated muscle mass and functional reduction. J Diabetes Investig. 2015;6:623–624. doi: 10.1111/jdi.12365.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit